 |
|
  |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
U.S. Centers for Disease Control and Prevention
• U.S. News
Vertex's HCV Drug VX-950 Gets Fast Track
December 9, 2005 This article is part of TheBody.com's archive. Because it contains information that may no longer be accurate, this article should only be considered a historical document. On Thursday, Vertex Pharmaceuticals Inc. announced the Food and Drug Administration has granted its hepatitis C drug "fast track" status, which formalizes agency assistance in drug development and in-process data submissions. FDA grants fast track designation, which can speed up the review process, to therapies that address an unmet need. Vertex's VX-950 therapy, which is in mid-stage human trials, has the potential to shorten the time hepatitis C patients spend on medication, the company said. Back to other news for December 9, 2005 This article is part of TheBody.com's archive. Because it contains information that may no longer be accurate, this article should only be considered a historical document. Associated Press 12.08.2005
This article was provided by U.S. Centers for Disease Control and Prevention. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update. |
E-Mail
Printer Friendly
Glossary
Share
